Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Dermagraft, Comparator · 2 trials · 1 indication
| Name | Type | Description |
|---|---|---|
| Dermagraft | DEVICE | Weekly application of Dermagraft(R) with standard care |
| Comparator | OTHER | Weekly application of standard care |
| Dermagraft(R) | DEVICE | Weekly application of Dermagraft(R) with conventional care |
| Conventional care | OTHER | Weekly application of conventional care |
Dermagraft is an investigational product being studied for the treatment of venous leg ulcers and diabetic foot ulcers. It is developed by Organogenesis Holdings Inc. and is currently in Phase 3 clinical development for these indications.
Dermagraft is developed by Organogenesis Holdings Inc., a company traded under the ticker ORGO. The product is being investigated for use in venous leg ulcers and diabetic foot ulcers.
Dermagraft is in Phase 3 clinical development. It is an investigational product and has not been approved by regulatory authorities. Clinical trials for venous leg ulcers and diabetic foot ulcers have been completed.
Dermagraft has been studied in Phase 3 clinical trials, including NCT00909870 for venous leg ulcers with 537 participants, and NCT01181440 and NCT01181453 for diabetic foot ulcers with 281 and 314 participants respectively. All trials are completed.
Dermagraft is also known as Comparator in some contexts. This alternative name may be used in clinical trial settings. The product is being developed by Organogenesis Holdings Inc. for venous leg ulcers and diabetic foot ulcers.